graph Evidence gap map comparisons
atezolizumab based treatmentanti-PD-(L)1durvalumab based treatmentnivolumab based treatmentpembrolizumab based treatmentsintilimab based treatment
atezolizumab alone atezolizumab plus bevacizumab plus carboplatin plus paclitaxel atezolizumab plus carboplatin plus nab-paclitaxel atezolizumab plus carboplatin plus paclitaxel atezolizumab plus pemetrexed and platin cemiplimab durvalumab alone nivolumab alone nivolumab plus SoC pembrolizumab alone pembrolizumab and pemetrexed plus platin pembrolizumab plus SoC sintillimab plus SoC
mNSCLC - L1 - all population 5       
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative 1   
mNSCLC - L1 - PDL1 positive 14              
mNSCLC - L1 - TMB>10Mb 1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population 3       
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT) 6            
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population 4       
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
Comparator:  vs Standard of Care (SoC);   vs placebo plus SoC;   vs pemetrexed plus platin;   vs bevacizumab plus carboplatin and paclitaxel;   vs atezolizumab plus carboplatin plus nab-paclitaxel;   vs carboplatin plus nab-paclitaxel;   vs nab-paclitaxel; 
Risk of bias:  low;   some concerns;   high;  NA;